Liver fluke drug proves safe in largest study yet

NCT ID NCT04230148

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the safety and effectiveness of the drug EGATEN (triclabendazole) in 301 people aged 6 and older with fascioliasis, a parasitic liver infection. Participants received two doses of EGATEN 12 hours apart and were followed for 90 days. The goal was to see if the drug is safe and can cure the infection by clearing symptoms and lab abnormalities.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FASCIOLIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fascioliasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Novartis Investigative Site

    Medellín, Antioquia, 050010, Colombia

  • Novartis Investigative Site

    Alexandria, 21131, Egypt

  • Novartis Investigative Site

    Cairo, 11617, Egypt

  • Novartis Investigative Site

    San Martín de Porres, Lima region, 31, Peru

  • Novartis Investigative Site

    Cusco, 84, Peru

  • Novartis Investigative Site

    Istanbul, Fatih, 34093, Turkey (Türkiye)

  • Novartis Investigative Site

    Gaziantep, Sehitkamil, 27310, Turkey (Türkiye)

  • Novartis Investigative Site

    Sur, 21280, Turkey (Türkiye)

  • Novartis Investigative Site

    Van, 65080, Turkey (Türkiye)

  • Novartis Investigative Site

    Qui Nhon, Binh Dinh, 590000, Vietnam